Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

  • Mark J. Selby,
  • John J. Engelhardt,
  • Robert J. Johnston,
  • Li-Sheng Lu,
  • Minhua Han,
  • Kent Thudium,
  • Dapeng Yao,
  • Michael Quigley,
  • Jose Valle,
  • Changyu Wang,
  • Bing Chen,
  • Pina M. Cardarelli,
  • Diann Blanset,
  • Alan J. Korman

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

  • Mark J. Selby, 
  • John J. Engelhardt, 
  • Robert J. Johnston, 
  • Li-Sheng Lu, 
  • Minhua Han, 
  • Kent Thudium, 
  • Dapeng Yao, 
  • Michael Quigley, 
  • Jose Valle, 
  • Changyu Wang
PLOS
x

Fig 1D is missing from Fig 1. Please see the corrected Fig 1 here.

thumbnail
Fig 1. Antitumor Responses of Anti-CTLA-4 and Anti-PD-1 Antibodies in Staged MC38 and CT26 Tumor Models.

A-B. Groups of 8–12 C57/BL6 mice were sourced from Taconic and subcutaneously injected with 2×106 MC38 cells. After tumors were measured on day 7, mice were randomized (58 mm3 mean tumor volume per group) and then treated with the designated mAb (200 μg/dose IP) followed by additional doses on days 10, 14, and 17. A. Groups were treated with 4 doses of single or combined agents. Anti-PD-1 vs control p = 0.0176; anti-PD-1 and anti-CTLA-4 vs control p< 0.0001. B. Sequential dosing, where 4 doses were given as 2 doses of one mAb followed by 2 doses of the other mAb and the converse. Anti-CTLA-4 followed by anti-PD-1 vs control p = 0.0250; anti-PD-1 followed by anti-CTLA-4 vs control p = 0.0015. Tumor volumes were measured twice weekly. The number of tumor-free (TF) mice per group is indicated. C-D. Groups of 10 BALB/c mice sourced from CRL (C) or HAR (D) Laboratories were subcutaneously injected with 1×106 CT26 cells. After tumors were measured on day 7, mice were randomized (C: 56 mm3 and D: 35 mm3 mean tumor volume) and then treated with the designated mAb (200 μg/dose IP) followed by additional doses on days 10, 14 (HAR mice), or 10, 14, 17 (CRL mice). Anti-CTLA-4 vs control p = 0.0035; anti-CTLA-4 and anti-PD-1 vs control p<0.0001. Tumor volumes were measured twice weekly. The number of TF mice per group is indicated.

https://doi.org/10.1371/journal.pone.0167251.g001

Reference

  1. 1. Selby MJ, Engelhardt JJ, Johnston RJ, Lu L- S, Han M, Thudium K, et al. (2016) Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS ONE 11(9): e0161779. pmid:27610613